Anagenics Limited · ASX:AN1
Anagenics — Cellmid — Shareholder Meeting (November 2016)
28 slides from Anagenics's shareholder meeting presentation, Nov 21, 2016
Slide 1: AGM Presentation – ASX Announcement
ASX ANNOUNCEMENT AGM PRESENTATION SYDNEY, Monday 21 November 2016: Cellmid Limited (ASX:CDY) provides the following presentation for the Annual General Meeting of the shareholders. End Contact: Maria Halasz, CEO T +612 9221 6830 @mariahalasz Cellmid Limited (ASX: CDY) Cellmid is an Australian life s
Slide 2: Cellmid Limited Annual General Meeting
CELLMID LIMITED ANNUAL GENERAL MEETING 21 November 2016 Maria Halasz CEO & Managing Director halasz@cellmid.com.au @mariahalasz
Slide 3: Important Notice
IMPORTANT NOTICE Summary information This presentation contains summary information about Cellmid Limited (Cellmid) and its activities as at November 2016. The information in this presentation is of a general nature and does not purport to be complete or contain all information that a prospective in
Slide 4: Cellmid (CDY:ASX)
CELLMID (CDY:ASX) Fully Paid Ordinary Shares (1 August 2016) 1,063,867,011 Market Capitalisation (18 November 2016) A$32 million 38,440,000 Unlisted options Cash Position (reported 30 September plus Placement) A$4.6 million Debt ($700K due Feb 2017, secured against R&D Tax Credit) A$1.2 million 3
Slide 5: Cellmid (CDY:ASX)
CELLMID (CDY:ASX) • Cellmid is an Australian life sciences company listed on the ASX (CDY:ASX) • Cellmid has three wholly owned subsidiaries with dedicated therapeutic targets: • Lyramid (chronic kidney disease, bone disorders and cancer including cancer diagnostic) • Kinera (heart failure) • Advang
Slide 6: Cellmid: Corporate and Business Structure
CELLMID: CORPORATE AND BUSINESS STRUCTURE Cellmid Limited Lyramid Limited Kinera Limited Advangen Limited CAB102 èvolis® CMK103 Chronic kidney disease Hair growth products Heart failure Bone disorders OTC Chronic heart conditions Brain tumour 5
Slide 7: 2016 Share Price Performance
2016 SHARE PRICE PERFORMANCE B5 B2 B4 0.040 B3 B6 B1 A5 0.035 A4 0.030 A1 A2 A3 0.025 0.020 0.015 JAN 16 FEB 16 MAR 16 APR 16 MAY 16 JUN 16 JUL 16 AUG 16 SEP 16 OCT 16 NOV 16 A1 Appointment of Elizabeth Masamune (4th Feb) B1 Midkine interviews with PharmaTelevision published (29th Jun) A2 Cellmid In
Slide 8: Board Members
BOARD MEMBERS Dr David King | Chairman Bruce Gordon | Non-Executive Director An experienced independent chairman with expertise in high Bruce is a seasoned audit partner and corporate finance specialist growth companies, Dr King has a track record in building with over 35 years’ industry experience.
Slide 9: FY2016 Highlights
FY2016 HIGHLIGHTS • April 2016: Strategic repositioning of Lyramid and Kinera (midkine pipeline companies) • April 2016: Fourth Midkine Symposium: new partnerships to enhance MK pipeline • May 2016: Record monthly sales for Advangen Japan ($575K in April 2016) • June 2016: Launching the évolis® Prof
Slide 10: évolis Australian Pharmacy Range
ÉVOLIS® AUSTRALIAN PHARMACY RANGE Men’s Women’s Men’s Women’s Men’s Women’s Tonic Tonic Shampoo Shampoo Active Pack Active Pack 9
Slide 11: évolis Australian Salon Range
ÉVOLIS® AUSTRALIAN SALON RANGE Youth Boost Life Vivid for youthful age defying hair for stronger, thicker, healthier hair for superior hydration and damage repair for colour treated hair 10
Slide 12: Advangen Japanese Range
ADVANGEN JAPANESE RANGE Jo-Ju scalp lotion Jo-Ju shampoo Lexilis scalp Lexilis shampoo for women for women lotion for men for men 11
Slide 13: évolis USA Range
9 0 = LL O EVOLIS® USA RANGE
Slide 14: The Problem
CELLMID© THE PROBLEM
Slide 15: The Problem
évolis Paula Duncan Actress |
Slide 16: The Problem Is Real
THE PROBLEM IS REAL 80 million 60% 47% COPYRIGHT © BY ADVANGEN/ ALL RIGHTS RESERVED
Slide 17: The Options
THE OPTIONS Topical Medicinal Surgical COPYRIGHT © BY ADVANGEN/ ALL RIGHTS RESERVED
Slide 18: The Alternative
THE ALTERNATIVE A NATURAL ALTERNATIVE TO COMBAT HAIR LOSS 17
Slide 19: COPYRIGHT © BY ADVANGEN/ ALL RIGHTS RESERVED
COPYRIGHT © BY ADVANGEN/ ALL RIGHTS RESERVED
Slide 20: The Ingredients
THE INGREDIENTS COPYRIGHT © BY ADVANGEN/ ALL RIGHTS RESERVED
Slide 21: The Believers
CELLMID © THE BELIEVERS ee MATER TEES STRRE TGR
Slide 22: The Believers
THE BELIEVERS 21 Play Video
Slide 23: Australian Market Strategy
AUSTRALIAN MARKET STRATEGY • Continue to grow the national pharmacy and salon distribution for évolis® • Currently ranging secured in 1,612 pharmacies, improve ranging • Build the national distribution to 400 salons by June 2017 • Increase market penetration in all retail channels by • Strong repres
Slide 24: Key Objectives – Consumer Health
KEY OBJECTIVES – CONSUMER HEALTH 1. USA: Direct to consumer sales, retail and salon distribution • Grow direct customer base to 10,000 by June 2017 • Retail launch in mid-2017 • Targeting $100 million in revenue in 7 years 2. Japan: Increase sales and profitability • Continue to grow sales through Q
Slide 25: Key Objectives – Lyramid and Kinera
KEY OBJECTIVES – LYRAMID AND KINERA 1. Build key opinion leader network for Lyramid and Kinera 2. Build on existing academic and commercial collaborations 3. Fund subsidiary companies directly • avoid dilution in Cellmid; and • add valuation upside 4. Complete preclinical development and commence cl
Slide 26: Financial Performance
FINANCIAL PERFORMANCE Results (AU$) 2014 2015 2016 Total revenue 1,898,037 2,930,518 4,571,599 141% Sales Revenue 1,150,931 1,842,804 3,120,367 171% Midkine revenue 1,009,188 99,263 205,390 R&D tax credit/grants 747,106 988,451 1,121,562 Total expenditure 5,023,890 6,301,547 8,098,979 61% R&D spendi
Slide 27: Summary
SUMMARY • Cellmid has a balanced portfolio of life sciences assets with strong global revenue growth expected from consumer health • Major potential upside from midkine drug therapeutics (partnerships and licenses) • Track record of delivering sales growth year on year, with sales up 72% in FY2016 •
Slide 28: Thank You
THANK YOU Cellmid Limited 15 Castlereagh Street Sydney NSW 2000 AUSTRALIA T: +61 2 9221 6830 F: +61 2 9233 8975 www.cellmid.com.au www.evolisproducts.com.au www.evolisprofessional.com.au